Novo Nordisk A/S CEO Mike Duchastal stated in an interview that pharmaceutical companies have only just begun to tap into the global weight loss market and should focus on expanding access to their medications. The head of the company behind Wegovy and Ozempic noted that while there are 110 million obese individuals in the United States, pharmaceutical firms currently serve only 10% to 15% of this population. The need to broaden drug accessibility was one reason Novo Nordisk agreed to lower prices for medications listed on former President Donald Trump's prescription drug website, TrumpRx. Starting in January, Novo Nordisk plans to reduce the wholesale price of Wegovy in the U.S. by 50% and Ozempic by 35%. The company hopes that the launch of an oral version of Wegovy this year will help it regain market leadership after losing ground to competitor Eli Lilly. Emil Larsen, Executive Vice President of International Operations at Novo Nordisk, indicated that in price-sensitive markets like India, price reductions could form part of its competitive strategy. He added that brand recognition would also help fend off rivals.